AMNESTEEM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMNESTEEM (AMNESTEEM).
Retinoid that binds to and activates retinoic acid receptors (RARs), thereby normalizing keratinocyte differentiation and reducing sebum production.
| Metabolism | Hepatic metabolism via CYP2C8, CYP3A4, and CYP2C9; undergoes glucuronidation and oxidation. Primary metabolites include 4-oxo-isotretinoin. |
| Excretion | Renal (65-83% as unchanged drug and metabolites), fecal (15-35% as metabolites) |
| Half-life | Terminal elimination half-life: 10-20 hours (mean 17 hours) in patients with normal renal function; prolonged in severe renal impairment |
| Protein binding | >99% bound, primarily to albumin |
| Volume of Distribution | 1.5-2.7 L/kg (mean 2.0 L/kg); indicates extensive tissue distribution including skin and sebaceous glands |
| Bioavailability | Oral: Approximately 25% (highly variable, 8-48% due to first-pass metabolism); enhanced 2-3 fold with high-fat meal |
| Onset of Action | Oral: 1-2 weeks for initial clinical improvement in acne; maximal effect after 4-6 months of therapy |
| Duration of Action | Sustained remission may persist for months to years after discontinuation; clinical effect wanes gradually |
| Molecular Weight | 300.44 |
0.5-1.0 mg/kg/day orally in 2 divided doses
| Dosage form | CAPSULE |
| Renal impairment | No adjustment necessary for renal impairment |
| Liver impairment | Contraindicated in patients with hepatic impairment |
| Pediatric use | 0.5-1.0 mg/kg/day orally in 2 divided doses |
| Geriatric use | No specific adjustment; use caution due to potential for increased adverse effects |
| 1st trimester | Contraindicated. Is associated with major congenital malformations including craniofacial defects, CNS abnormalities, and cardiovascular defects. Pregnancy must be excluded before therapy. |
| 2nd trimester | Contraindicated. Same teratogenic risks as first trimester; fetal harm can occur at any point during pregnancy. |
| 3rd trimester | Contraindicated. Continued risk of fetal harm; elective termination advised if exposure occurs. |
Clinical note
Comprehensive clinical and safety monograph for AMNESTEEM (AMNESTEEM).
| Placental transfer | Isotretinoin crosses the placenta readily; animal studies show embryotoxicity and teratogenicity. Human data confirm extensive placental transfer. |
| Breastfeeding | Isotretinoin is excreted in breast milk in small amounts; however, due to risk of potential adverse effects in the nursing infant (including risk of tumor induction), breastfeeding is not recommended during therapy and for at least 8 days after the last dose. |
■ FDA Black Box Warning
Contraindicated in pregnancy (Category X) due to teratogenicity including CNS, craniofacial, cardiovascular, and thymic abnormalities; also associated with spontaneous abortion and premature births.
| Serious Effects |
PregnancyWomen of childbearing potential unless compliant with pregnancy prevention programKnown hypersensitivity to isotretinoin or any componentConcomitant use with tetracyclines (risk of pseudotumor cerebri)
| Precautions | Risk of pseudotumor cerebri (especially with tetracyclines); psychiatric disorders (depression, suicide); pancreatitis; hypertriglyceridemia; hepatotoxicity; hearing impairment; inflammatory bowel disease; photosensitivity; corneal opacities; elevated ESR. |
| Food/Dietary | Take with meals containing fat (e.g., whole milk, peanut butter) to enhance absorption. Avoid excessive vitamin A supplements (including multivitamins with vitamin A) to prevent toxicity. Grapefruit juice may increase drug levels; limit intake. |
Loading safety data…
| Lactation Rating | Avoid |
| Teratogenic Risk | Amnesteem (isotretinoin) is a known human teratogen. All trimesters: extremely high risk of major fetal malformations (CNS, cardiovascular, facial dysmorphism), spontaneous abortion, and premature birth. Pregnancy is absolutely contraindicated. Prescription requires adherence to a Risk Evaluation and Mitigation Strategy (REMS) program with mandatory pregnancy testing and contraception. |
| Fetal Monitoring | All patients: two negative pregnancy tests before initiation, monthly pregnancy tests during therapy, and one post-therapy at 5 weeks. LFTs, lipid profile, renal function, CBC, and CPK at baseline and periodically. Monitor for psychiatric symptoms (depression, suicidality) and mucocutaneous adverse effects. Fetal monitoring if pregnancy occurs (ultrasound for anomalies). |
| Fertility Effects | Reversible impairment of spermatogenesis and ovarian function reported. No permanent negative impact on fertility after discontinuation. Use effective contraception during and for 1 month after stopping therapy. |
| Clinical Pearls | Isotretinoin (Amnesteem) is highly teratogenic; two negative pregnancy tests are required before initiation. iPledge program mandatory. Monitor for mood changes, suicidal ideation. Avoid tetracyclines (pseudotumor cerebri risk). Baseline and monthly liver enzymes, lipids, pregnancy tests. Dry skin and cheilitis are universal; use emollients and lip balm. Use with caution in patients with history of IBD. Drug interaction with St. John's wort may reduce efficacy. |
| Patient Advice | This medication can cause severe birth defects; you must use two forms of effective contraception one month before, during, and one month after treatment. · You must enroll in the iPledge program and complete monthly pregnancy tests. · Do not become pregnant; if you do, stop the drug immediately and contact your doctor. · Avoid blood donation during and for one month after therapy. · Report any vision changes, severe headache, nausea, or mood changes (depression, aggression, suicidal thoughts) immediately. · Avoid waxing, dermabrasion, or laser treatments during and for 6 months after therapy. · Expect dry lips, skin, and eyes; use moisturizers, lip balm, and artificial tears. · Do not take tetracycline antibiotics (like doxycycline) while on this drug. · Limit alcohol intake as it may increase triglyceride levels. · Take with food to improve absorption and reduce stomach upset. |